European Commercial Roll-out continues with Poland Agreement
| Stock | Memphasys Ltd (MEM.ASX) |
|---|---|
| Release Time | 5 Aug 2026, 8:44 a.m. |
| Price Sensitive | Yes |
Memphasys Secures Polish Agreement for Felix System
- Approximately A$350,000 contracted value over two years
- TK Biotech appointed exclusive partner for Poland
- Poland joins Italy and UK as commercial markets
Memphasys Limited (ASX: MEM) has entered into an exclusive commercialization agreement with TK Biotech Sp. z o.o. for the sale and commercialization of the Felix System in Poland. This agreement marks a significant step in the company's European commercial roll-out following CE Mark approval. The agreement comprises an initial three-month evaluation period followed by a two-year commercial term with a minimum contracted value of approximately A$350,000. TK Biotech will be responsible for developing relationships with IVF clinics, embryologists, and fertility specialists in Poland, while Memphasys will provide product training, technical support, and marketing materials. The agreement reflects Memphasys' in-country commercial partner model and includes performance incentives to support sales above the minimum contracted commitment.
Approximately A$350,000 contracted value over two years
Memphasys is focused on converting strong interest into contracted commercial partnerships and revenue. The company has appointed a Director of Commercial Operations - Europe to drive the sales process and support partner onboarding.